financetom
Business
financetom
/
Business
/
Snowflake Faces Spending Headwinds as Macro Uncertainty Weighs, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Snowflake Faces Spending Headwinds as Macro Uncertainty Weighs, UBS Says
May 26, 2025 9:39 AM

11:26 AM EDT, 05/16/2025 (MT Newswires) -- Snowflake (SNOW) is not immune to a declining spending trend as customers work around tighter budgets due to macroeconomic uncertainty, despite data analytics and machine learning being a priority, UBS Securities said in a note emailed Friday.

The investment firm said that feedback from the data storage company's enterprise partners indicates decent performance, but not standout. "Snowflake, on several occasions, has outperformed partner feedback," UBS added.

Both Snowflake and Databricks are gaining market share by taking workloads from legacy platforms like Oracle (ORCL), Teradata ( TDC ) , and Hadoop, according to the note.

UBS said Snowflake's AI product, Cortex, is starting to see traction, which could open up monetization opportunities in the future. However, this is still in its early stages and not yet a significant growth driver.

The firm reiterated a neutral rating on the company's stock with a $200 price target.

Price: 183.11, Change: +0.14, Percent Change: +0.08

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mesoblast Says Ryoncil Receives FDA Approval for Acute Graft Versus Host Disease; Shares Rise Pre-Bell
Mesoblast Says Ryoncil Receives FDA Approval for Acute Graft Versus Host Disease; Shares Rise Pre-Bell
Dec 19, 2024
04:14 AM EST, 12/19/2024 (MT Newswires) -- Mesoblast (MESO) said late Wednesday the US Food and Drug Administration has approved its mesenchymal stromal cell therapy Ryoncil for steroid-refractory acute graft versus host disease in children 2 months and older, adolescents and teenagers. Shares of Mesoblast surged 51% in premarket activity Thursday. The company said Ryoncil is the first FDA-approved treatment...
Leishen Energy Prices $5.5 Million Initial Public Offering
Leishen Energy Prices $5.5 Million Initial Public Offering
Dec 19, 2024
03:48 AM EST, 12/19/2024 (MT Newswires) -- Leishen Energy (LSE) said late Wednesday it priced its initial public offering of 1.4 million shares at $4 per share for expected gross process of $5.5 million. The company said the shares are expected to begin trading on the Nasdaq Capital Market on Thursday under the LSE ticker. The Chinese clean-energy equipment provider...
Analysis-Behind a potential Honda and Nissan tie-up, the existential threat posed by Chinese EVs
Analysis-Behind a potential Honda and Nissan tie-up, the existential threat posed by Chinese EVs
Dec 19, 2024
TOKYO (Reuters) - Some unions are born of necessity, others from convenience. In the case of Honda ( HMC ) and Nissan's ( NSANF ) potential merger, it is mostly defensive as Chinese rivals take the world by storm. While the challenge from China's seemingly boundless EV expertise looms large for all traditional automakers, for Japan it represents a threat...
Taiwan's China Airlines splits $11.9 bln aircraft deal between Boeing and Airbus
Taiwan's China Airlines splits $11.9 bln aircraft deal between Boeing and Airbus
Dec 19, 2024
TAIPEI, Dec 19 (Reuters) - Taiwan's China Airlines will split an order for its long-haul fleet renewal between Boeing ( BA ) and European rival Airbus and buy freighters from the U.S. planemaker in a closely watched deal worth almost $12 billion. Taiwan's largest carrier had been considering the 777X, of which the 777-9 is a variant, and A350-1000 as...
Copyright 2023-2026 - www.financetom.com All Rights Reserved